Microcephaly Genetic Deficiency in Neural Progenitors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to: I. Compare neuroradiological phenotype and cognitive functioning of MCPH patients caused by ASPM mutations already characterized and published (Passemard et al. 2009a) with other MCPH-related patients (patients with MCPH1, WDR62, CDK5RAP2, CEP 152, CENPJ, STIL, or PCNT mutations) II. Describe the neuro-radiological and cognitive phenotype of microcephalic patients suffering from Fanconi anemia, and compared them to subjects with: Fanconi anemia but normal OFC (head circumference) MCPH patients Healthy control subjects Our hypothesis is that mutations in genes responsible of microcephaly impact differentially cortical brain development and functioning

Detailed Description
-----------------
Phenotyping study on 2 different cohorts of rare disease affected patients: Group1: MCPH (including different MCPH subtypes) Group2: Fanconi Anemia (with or without microcephaly) Inclusion criteria: Common to each group: Age > 3 years Access to french Social Security No contraindication for MRI Group1: Primary microcephaly without gross malformation within or extra nervous central system OFC < -2SD at birth and < -3 SD after age 6months Mutation in one MCPH gene Group2: Proven Fanconi Anemia with: Positive chromosome breakage blood test One of the 3 following elements: FANCD2 positive test Fibroblast sensitivity to mitomycin Mutation in one FANC gene Control subjects: No antecedent Normal education Aims: Description of neurological, neuropsychological and radiological phenotype for each group Phenotype comparison: groups 1&2 group1 or 2 with control subjects different MCPH subtypes within group1 with or without microcephaly within group2 Epidemiological data on these rare diseases in our population Protocol: Patients from both groups and control subjects will be evaluated in CIC for 1 day ½. They will be examined by a child neurologist and a geneticist. All of them will have cranial MRI (1.5Tesla). Neuropsychological assessment will be performed (Wechsler scales) for patients and control subjects.

Official Title
-----------------
Microcephaly Genetic Deficiency in Neural Progenitors: Genotyping, Phenotyping and Functional Neuro-anatomy and Neurobiology Comparative Primitive Microcephaly (MCPH) and the Fanconi Anemia (FA)

Conditions
-----------------
Microcephaly

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged ≥ 3 years: Microcephalic phenotype consistent with MCPH (recruitment already done as part of a network GIS-Rare Diseases Institute). MCPH patients have already been selected in the cohort Robert Debré. Holders of a Fanconi anemia characterized in terms of cytogenetics, enzyme and/or molecular (patients in the cohort Saint Louis followed by the KRC rare aplastic anemia) Healthy controls aged ≥ 5 years siblings of patients with Fanconi Anemia Exclusion Criteria: Patients with Fanconi anemia: bone marrow < 3 years Post-transplantation neurological complications developmental, genetic or environmental additional pathology

Ages Eligible for Study
-----------------
Minimum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Microcephaly<br>Microcephaly Intellectual abilities Cranial MRI | |
| FANCONI ANEMIA<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare neuroradiological phenotype and cognitive functioning with other MCPH-related patients | The purpose of this study is to: Compare neuroradiological phenotype and cognitive functioning of MCPH patients caused by ASPM mutations already characterized and published (Passemard et al. 2009a) with other MCPH-related patients (patients with MCPH1, WDR62, CDK5RAP2, CEP 152, CENPJ, STIL, or PCNT mutations) | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Establish a clear organizational chart for the diagnosis of primary microcephaly | I. Establish a clear organizational chart for the diagnosis of primary microcephaly from the detailed description of the patient's phenotype II. Establish epidemiological data on the molecular genetic causes involved in human primary microcephaly | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MCPH, FANCONI ANEMIA